My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

77.50 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Sep 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,902
Open 77.50
Bid (Size) 77.02 (3)
Ask (Size) 77.05 (2)
Prev. Close 77.50
Today's Range 77.50 - 77.50
52wk Range 61.24 - 82.41
Shares Outstanding N/A
Dividend Yield 1.33%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
European Advisory Panel Recommends Two AstraZeneca Drugs For Approval
AstraZeneca and Amgen secure CHMP support for Tezspire in nasal polyps and Koselugo in neurofibromatosis after strong Phase 3 trial results. 
Via Benzinga
Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market
The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a... 
Via MarketMinute
Topics Economy Intellectual Property

Performance

YTD
+17.6%
+17.6%
1 Month
-2.7%
-2.7%
3 Month
+9.7%
+9.7%
6 Month
+4.6%
+4.6%
1 Year
+0.5%
+0.5%

More News

Read More
Is the Market Bullish or Bearish on AstraZeneca?
Via Benzinga
Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease
Via Stocktwits
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era
Via MarketMinute
Retail Buzz Builds As AstraZeneca’s Tagrisso Combo Extends Lung Cancer Survival To Nearly 4 Years
Via Stocktwits
Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production
Via MarketMinute
Topics Artificial Intelligence Economy Government
Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Via MarketMinute
AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol
From AstraZeneca
Via Business Wire
AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial
Via Benzinga
Advancing Cancer Research Brings New Hope for Patients Worldwide
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Advancing Cancer Research Brings New Hope for Patients Worldwide
Via FinancialNewsMedia
Topics Artificial Intelligence Intellectual Property
SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
From AstraZeneca
Via Business Wire
GSK Stock Climbs After-Hours On $30B US Investment Pledge As Trump Pressures Big Pharma To Build In America
Via Stocktwits
Topics Artificial Intelligence Government World Trade
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
Via Benzinga
Topics Government
The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health
Via MarketMinute
Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs
Via Benzinga
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
Via Investor's Business Daily
Topics Government
FDA Expands Approval For AstraZeneca's Drug For Pediatric Patients With Rare Type Of Cancer
Via Benzinga
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Via Benzinga
Topics ETFs Government
AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study
Via Benzinga
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again
Via Investor's Business Daily

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?
Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
What exchange does AstraZeneca PLC - American Depositary Shares trade on?
AstraZeneca PLC - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the Nasdaq Stock Market
What is the current price of AstraZeneca PLC - American Depositary Shares?
The current price of AstraZeneca PLC - American Depositary Shares is 77.50
When was AstraZeneca PLC - American Depositary Shares last traded?
The last trade of AstraZeneca PLC - American Depositary Shares was at 09/22/25 04:15 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.